Literature DB >> 31494987

Epidemiology of hidradenitis suppurativa in Germany - an observational cohort study based on a multisource approach.

N Kirsten1, J Petersen1, K Hagenström1, M Augustin1.   

Abstract

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory skin disease. In Germany, there are no population-based data on the epidemiology of HS.
OBJECTIVES: The objective of this study was to examine the occurrence of HS in inpatient as well as in outpatient settings.
METHODS: We used three data sources for analysing the prevalence, incidence and case-related occurrence of HS in different settings: data of two German statutory health insurance (SHI) companies and hospital discharge data provided by the Federal Statistical Office. The studied period was from 2010 to 2015.
RESULTS: In a representative sample of about 2.3 million insurees (out of 5.9 million total persons) of the SHI DAK-Gesundheit, 791 were diagnosed with HS in 2010. This coding prevalence of 0.03% is in accordance with the data of another SHI (Barmer) on about 9 million total insurees. In 2015, at least 34.7% of incident persons with HS had one potential misdiagnosis in 2014.
CONCLUSION: This population-based study analyses the prevalence and incidence of HS in Germany. The coding prevalence of 0.03% observed in two independent SHI data sets is lower than expected. The findings of considerable potential misdiagnosis add to the underdiagnosis of HS in general and underline the need for future strategies to early detection and valid diagnosis of HS.
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Entities:  

Year:  2019        PMID: 31494987     DOI: 10.1111/jdv.15940

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  7 in total

1.  Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.

Authors:  Sophie Glatt; Gregor B E Jemec; Seth Forman; Christopher Sayed; George Schmieder; Jamie Weisman; Robert Rolleri; Seth Seegobin; Dominique Baeten; Lucian Ionescu; Christos C Zouboulis; Stevan Shaw
Journal:  JAMA Dermatol       Date:  2021-11-01       Impact factor: 10.282

Review 2.  [Epidemiology, patient quality of life, and treatment costs of hidradenitis suppurativa/acne inversa].

Authors:  N Kirsten; V Frings; G D Nikolakis; D Presser; M Goebeler; C C Zouboulis; M Augustin
Journal:  Hautarzt       Date:  2021-07-05       Impact factor: 0.751

3.  Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors.

Authors:  Andreas Pinter; Georgios Kokolakis; Juergen Rech; Mona H C Biermann; Benjamin M Häberle; Jan Multmeier; Maximilian Reinhardt
Journal:  Dermatol Ther (Heidelb)       Date:  2020-06-04

4.  The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa.

Authors:  Alex Bató; Valentin Brodszky; L Hunor Gergely; Krisztián Gáspár; Norbert Wikonkál; Ágnes Kinyó; Ákos Szabó; Zsuzsanna Beretzky; Andrea Szegedi; Éva Remenyik; Norbert Kiss; Miklós Sárdy; Fanni Rencz
Journal:  Qual Life Res       Date:  2021-02-03       Impact factor: 4.147

5.  New insights in hidradenitis suppurativa from a population-based Dutch cohort: prevalence, smoking behaviour, socioeconomic status and comorbidities.

Authors:  Lisette M Prens; Klasiena Bouwman; Lisa D Troelstra; Errol P Prens; Behrooz Z Alizadeh; Barbara Horváth
Journal:  Br J Dermatol       Date:  2022-05       Impact factor: 11.113

6.  Self-Reported Hidradenitis Suppurativa Severity: Is It Useful for Clinical Practice?

Authors:  Piotr K Krajewski; Servando E Marrón; Lucía Tomas Aragones; Yolanda Gilaberte-Calzada; Jacek C Szepietowski
Journal:  Dermatol Ther (Heidelb)       Date:  2022-03-10

7.  Identifying Unmet Care Needs and Important Treatment Attributes in the Management of Hidradenitis Suppurativa: A Qualitative Interview Study.

Authors:  Damon Willems; Mickael Hiligsmann; Hessel H van der Zee; Christopher J Sayed; Silvia M A A Evers
Journal:  Patient       Date:  2021-08-09       Impact factor: 3.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.